Asia non-deal roadshow March 2018revenues notably Manuka Hemp Honey Agreement reached with...

INVESTOR PRESENTATIONAsia non-deal roadshow – March 2018

ASX:BDA MARCH 20182

Major shareholders % Holding

Jo Patterson 10.2%

Noir Ted Pty Ltd (Craig Weller) 8.9%

Citicorp Nominees Pty Limited 8.5%

J P Morgan Nominees Australia Ltd 8.5%

HSBC Custody Nominees (Australia) Ltd 3.7%

AWJ Family Pty Ltd 3.6%

Calama Holdings Pty Ltd 2.7%

Mr Hongjun Song 2.1%

GP Securities Pty Ltd 1.8%

Board & ManagementJo Patterson Chief Executive Officer

Craig Weller Chief Operating Officer

Simon O’Loughlin Independent Chairman

Simon Taylor Non-Executive Director

Mickey Perret Non-Executive Director

56M $32.7M

$4.9M

$0.72 – $0.09

Nil

ASX:BDA MARCH 20183

Medicinal cannabis import licences granted – along with the delivery of Linnea’s proprietary oil and powder

‘Trial ready’ cannabis wafer development progressing well – Phase I Clinical Trials set to commence near term

Company assessing revenue opportunities through sale of cannabis oils via Therapeutic Goods Administration Special Access Category B Scheme

Exclusive partner, iX Biopharma secured patent protection for WaferiX delivery method in China – IP now patent protected across key Asia markets and 20 other key markets

Bod launches MamaCare pregnancy supplement – Company to leverage established relationships to push growth in lucrative Asian markets

Strong distribution footprint growth continuing – Company now has access to over 950 individual stores, pharmacies and retailers

Multiple products to be launched in coming months – strong uptake expected driving additional revenues notably Manuka Hemp Honey

Agreement reached with pharmaceutical broker, In2Pharma secured – allows for two-tier strategy and considerably increase sales and coverage of distribution footprint

Board and Management continue aggressively assessing international opportunities - developments expected near term

Bod is an early mover

in Government

regulated import

licensing and product

trials and

development.

Investment Highlights

ASX:BDA MARCH 20184

CANNABIS BUSINESS:

• A logical extension of our natural medicines portfolio

• Medicinal Cannabis Import licenses granted

• Clinical trials process progressing pleasingly – to be commenced shortly

• ‘Trial ready’ sublingual wafer development progressing well via partner and leading pharmaceutical company, iX Biopharma

• Additional licenses to be considered – ensuring access to other verticals

• Focused on R&D with commercialisation of OTC and therapeutic products:

• OTC – Near term formulation of cosmetics through Linnea partnership

• Therapeutic – Developed following Phase I Clinical Trials

DISTRIBUTION BUSINESS:

• Bod now has access to over 950 ‘doors’ – more to follow near term

• Provides platform for revenue growth and channel to market through both Pharmacy and Doctors

• Distribution footprint ideally suited for Cannabis based products

• Growth expected from International sales channels via Daigou relationships

• Products to be launched near term provide access to top five most lucrative pharmacy segments

Two Integrated Business Units

ASX:BDA MARCH 20185

MEDICINAL CANNABIS

A partnership with global players.

ASX:BDA MARCH 20186

ECs315

Standardised & reproducible extract

Wafer iX and Ecs315 combined products are patent protected across

Asia and 20 other countries

Significant licencing opportunities through large pharmaceutical

companies through iX Biopharma

Unique Extract World wide rights to finished product (Ecs135+WaferiX)World wide patents held on WaferiX

ASX:BDA MARCH 20187

• Linnea’s patented growing, cloning and extraction

process maximises concentration of CBD, while not changing the natural profile of the Cannabis plan

• Only reproducible Phytocomplex extract globally ensures greater certainty in the outcome

• Bod retains fill ownership and commercialization of end products

Linnea Advantage – unique among global players

ASX:BDA MARCH 20188

Linnea’s Cannabis Extracts are suitable for*

• Pharma

• Food Supplements

• Medical Devices

• Cosmetics

*according to National Local Legislation Worldwide

(not necessarily all areas which the Company will pursue)

Key:Pharma Food

SupplementCosmetic

Applications

OIL EXTRACTS

for oil based formulations

SOLUBLE EXTRACTS

for water based formulations

DRY EXTRACTS

for solid formulations

PURE COMPOUNDS

For solid and liquid formulations

ASX:BDA MARCH 20189

Agreement to develop a cannabis wafer product using patented delivery methods

• iX Biopharma are a leading, Singapore Stock Exchange listed pharmaceutical company (SGX:42C)

• Product to be based on proven and proprietary ‘WaferiX™’ technology

• BDA to supply iX Biopharma with a range of cannabis extracts including oils and raw materials

• Development of ‘trial ready’ product already underway at iX’s Australian facilities – defrays all import costs and risks

• Bod entitled to exclusively own intellectual property rights to the name and packaging of finished, commercialised product

• Significant development in the commencement of Phase I Clinical Trials to test safety, tolerability and pharmacokinetics of its unique cannabis extracts for use in natural medicines

• iX Biopharma recently secured patent protection for WaferiX technology throughout China – meaning Bod’s products and IP are now protected across Asia

Exclusive Agreement with iX Biopharma

Manufacturing and commercialisation agreement with a leading pharma company

ASX:BDA MARCH 201810

Supply agreement with Linnea

iXlicence

deal

Import licencessecured

Phase 1 Design

Raw material imported

Formulate trial product

Ethics approval

First patient visit

Trial results

Phase 1a & b Safety. Tolerability and Pharmacokinetics

✓ ✓✓✓

Pathway to Phase 1 Trial

Export Opportunities

Further R&D and line extensions.

Health/recreational/THC:CBD

Licensing opportunities with

large PharmaPhase 2 & 3

identification of multiple therapeutic

indications


Faster path to market with less complexity in clinical trials

• Nausea and vomiting

• Anti-inflammatory

• Muscle relaxation

• Increased brain function

• Anxiety relief

• Allergy and asthma

• Sleep improvement

• Anti-ageing

Phytocomplex Uses And Indications

consistent extract=

stable clinical trial substrate

Administration via patented sublingual wafer

Phase 1 Pharmacokinetic trial designed and partner confirmed

First Patient First Visit - April 2018

3 month duration (reduced from the original 10 months)

Following initial results move to Phase II

Nausea relief and vomiting, increased brain function, anxiety relief, sleep improvement


OTHER COMMERICAL OPPORTUNITIES

Potential Sale of Cannabis Oil Export of Linnea’s Nioskin range from Europe to Asia

International distribution deals Vertical Integration

• Bod has successfully imported Linnea’s CBD oil

• Sales of ECs135 Oil though SAS to commence for local Australian consumption market to commence Q4

• Estimated price $AUD550 per 50mL for 5% CBD oil)

• Linnnea’s Nioskin is a proprietary base cream that operates as a transporter of the active (Cannabis) ingredient

• Currently being formulated and manufacturer in Italy through Linnea partnerships

• Immediate opportunity to sell through UK market

• Bod in advanced discussions with international counterparties to import unique cannabis and hemp based products

• Leveraging the existing paths to market through Pharmacy

• Positioned in therapeutic skincare segment

• Bod exploring the commercial merit of vertical integration

• Filling supply gaps by offering Southern Hemisphere operations

• Leveraging current partnerships and sharing knowledge bank

There are a number of other commercial opportunities available to Bod through leveraging its granted import licence and relationships with strategic parties such as Linnea and iX Biopharma


Peer Comparisons

CompanyASX Code Market Cap*

Cannabis

ProductionNutraceuticals Animal Health Growing Equipment Cosmetic

Cann Group Ltd CAN $427.9m ✓

Auscann Group Holdings Ltd AC8 $430.9m ✓ ✓ ✓

The Hydroponics Co Ltd THC $158.35m ✓ ✓

MMJ Phytotech Ltd MMJ $122.3m ✓ ✓

Creso Pharma Ltd CPH $117.2m ✓ ✓ ✓

MGC Pharmaceuticals Ltd MXC $129.7m ✓ ✓

Roto-Gro International Ltd RGI $47.38m ✓

Bod Australia Ltd BDA $32.7m ✓

Cannpal Animal Therapeutics Ltd CP1 $27.95m ✓


DISTRIBUTION

Revenue generating, and a

footprint to access markets.


Established Footprint and Channels to Market


Recently secured MamaCare distribution deal

Provides access to growing market

Complimentary addition the the Company’s product range with significant Asian market potential

• MamaCare supplement and skincare range includes all nutrients required before and after pregnancy

• Immediately revenue-accretive with brand already generating revenue

• Bod currently managing all marketing, sales and distribution of the brand

• Considerable uptake witnessed through Bod’s established channels to market

• Company to leverage key daigou relationships to push product in lucrative Asian markets

• Key product advantages include a more pleasant taste, broader ingredient range and ease of absorption compared to tablets

• No established market leader and little competition in the pregnancy supplement market provides significant opportunity for the Company


Strategic Agreement With Manuka Pharma

HOA to develop and manufacture high methylglyoxal hemp-honey product line

Highly complimentary expansion of product portfolio with numerous applications being explored

• Leading New Zealand producer, Manuka Pharma, to develop and manufacture product

• BDA to import finished product and package under any brand and logo chosen by the Company

• Bod Australia to own all associated IP and global distribution rights

• Products to be sold through Bod’s established sales channels and Daigou networks – sales to commence first half CY2018

• Global import demand for honey is estimated to be ~US2.1 billion – key markets include Australia, UK, Hong Kong and China

• High volumes markets pay circa $21 - $28 per kg with higher grade and medicinal standards selling for up to $1,000 per kg

• Manuka Honey provides key health benefits such as reduction in reflux, combatting staph infection and improving sleep quality

• Additional supplements and cosmetic products to be developed following hemp honey launch


Significant Distribution Channel Growth

• Strong progress in growing distribution with current product suite

• Ongoing expansion of product range will help grow distribution channels and increase revenues per door

• Additional growth expected during current quarter – banner group discussions remain ongoing


Average margin across the business is

currently56%

Current Product Portfolio

Representing 7 brands

and over 30 SKU’s


Distribution Summary - Near Term Business Strategy


Near Term Value Drivers

Receipt of cannabis powder and oil expected in coming weeks

Revenues to be realised from sale of Linnea’s proprietary cannabis oils - through Special Access Scheme Category B

‘Trial ready’ sublingual wafer to be finalised shortly – Phase I Clinical trials to commence shortly thereafter

Distribution footprint continues to grow – ongoing discussions with banner groups progressing well

Introduction of new products to further underpin revenue growth. Bod set to unlock lucrative IBS, Stress and Anxiety markets as well as Mauka Honey export opportunities

Additional cannabis licencesto be considered – vertical integration to be assessed where possible

Cannabis based cosmetic products expected to be launched this calendar year

International growth opportunities being assessed – developments expected near term

Jo Patterson – Chief Executive Officer+61 2 9199 5018

ASX:BDA

bodaustralia.com

Thank you


DISCLAIMER

This presentation has been prepared by Bod Australia Limited (Bod) and contains background information about Bod current at the date of this presentation. The presentation is in summary form and does not purport to be all-inclusive or complete. Recipients should conduct their own investigations and perform their own analysis in order to satisfy themselves as to the accuracy and completeness of the information, statements and opinion contained in this presentation.

This presentation is for information purposes only. Neither this presentation nor the information in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sale of shares. This presentation does not constitute investment advice and has been prepared without taking into account the recipient’s investment objectives, financial circumstances or particular needs and the opinions and recommendations in this presentation are not intended to represent recommendations of particular persons. Recipient should seek professional advice when deciding if an investment is appropriate.

All securities transactions involve risk, which include (amongst others)

the risk of adverse or unanticipated market, financial or political developments. To the fullest extent permitted by law, Bod and their officers, employees, agents and advisers do not make any presentation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of any information, statement, opinions, estimates, forecasts or other representations contained in this presentation. No responsibility for any error or omissions from this presentation arising out of negligence or otherwise is accepted.

This presentation may include forward-looking statements. Forward-looking statements are only predications and are subject to risk, uncertainties and assumptions that are outside the control of Bod. Actual values, results or events may be materially different to those expressed or implied in this presentation. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. Subject to any continuing obligations under the applicable law and ASX Listing Rules, Bod do not undertake any obligations to update or revise any information or any of the forward-looking statements in this presentation of any changes in events, conditions or circumstances on which any such forward-looking statement is based.

Asia non-deal roadshow March 2018revenues notably Manuka Hemp Honey Agreement reached with...

Documents

Transcript of Asia non-deal roadshow March 2018revenues notably Manuka Hemp Honey Agreement reached with...